510(k) Report

510(k) · Cleared

Cleared

CARA System

K252500510(k) TraditionalCleared Feb 20, 2026196-day reviewClass II21 CFR 892.1650

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Cara Medical, Ltd. · OWB Interventional Fluoroscopic X-Ray System

Cleared on Feb 20, 2026 as substantially equivalent to K212442 (Cydar, Ltd., 2021) after a 196-day review. Its family tree reaches back 9 generations to 1991.

Decided
Feb 20, 2026
Review
196 days
Class
Class II
Product code
OWB
Recalls
None
Predicates
1

Its longest line of descent runs back 9 generations to K913770 (1991). 28 ancestors in all, the oldest K852353 (1985). No later device cites it as a predicate yet.

  1. Root · 9 generations backK913770 Advantage V.S. CT/MR Rad Diagnostic WorkstationGeneral Electric Co. · 1991
  2. 5 generations between
  3. 3 generations backK151598 VesselNavigator Rel. 1.0Philips Medical Systems Nederland B.V. · 2015
  4. 2 generations backK160088 Cydar EVCydar, Ltd. · 2016
  5. 1 generation backK212442 Cydar EV (Series B) and Cydar EV MapsCydar, Ltd. · 2021
  6. This deviceK252500 CARA SystemCara Medical, Ltd. · 2026
Show all 9 generations
  1. Root · 9 generations backK913770 Advantage V.S. CT/MR Rad Diagnostic WorkstationGeneral Electric Co. · 1991
  2. 8 generations backK960613 GE Advantage Windows Review WorkstationGE Medical Systems · 1996
  3. 7 generations backK020483 Advantage Workstation 4.1GE Medical Systems · 2002 · Recalled
  4. 6 generations backK052995 Advantage Workstation 4.3.GE Healthcare · 2005 · Recalled
  5. 5 generations backK092639 Innova Vision, Model S18751VN, Innova Trackvision, Model S18751VT…GE Medical Systems SCS · 2009
  6. 4 generations backK121772 Allura 3D-RA Rel 6, 3D Roadmap Rel 1, MR-CT Roadmap Rel 1Philips Medical Systems Nederland B.V. · 2013
  7. 3 generations backK151598 VesselNavigator Rel. 1.0Philips Medical Systems Nederland B.V. · 2015
  8. 2 generations backK160088 Cydar EVCydar, Ltd. · 2016
  9. 1 generation backK212442 Cydar EV (Series B) and Cydar EV MapsCydar, Ltd. · 2021
  10. This deviceK252500 CARA SystemCara Medical, Ltd. · 2026
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−9K913770Advantage V.S. CT/MR Rad Diagnostic WorkstationGeneral Electric Co.1991—
−8K960613GE Advantage Windows Review WorkstationGE Medical Systems1996—
−7K020483Advantage Workstation 4.1GE Medical Systems20022
−6K052995Advantage Workstation 4.3.GE Healthcare20054
−5K092639Innova Vision, Model S18751VN, Innova Trackvision, Model S18751VT, Innova…GE Medical Systems SCS2009—
−4K121772Allura 3D-RA Rel 6, 3D Roadmap Rel 1, MR-CT Roadmap Rel 1Philips Medical Systems Nederland B.V.2013—
−3K151598VesselNavigator Rel. 1.0Philips Medical Systems Nederland B.V.2015—
−2K160088Cydar EVCydar, Ltd.2016—
−1K212442Cydar EV (Series B) and Cydar EV MapsCydar, Ltd.2021—
0 (this device)K252500CARA SystemCara Medical, Ltd.2026—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
198510
198710
199310
199410
199510
199610
199710
199830
199910
200110
200430
200610
200810
201210
201410
FIG. 1 — Lineage of K252500, 1991–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in OWB? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new OWB device

  1. #1 K251602 Alphenix, INFX-8000V/B, INFX-8000V/S, V9.6…score 18.3 · 18 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K212442Cydar EV (Series B) and Cydar EV Maps
Summary page 5
…em is substantially equivalent to the following predicate device: • Device Tradename: Cydar EV (Series B), also referred to as Cydar EV Maps • 510(k) Number: K212442 • Company: Cydar Medical • Common or Usual Name: Interventional Fluoroscopic X-Ray System • Classification Name…
Cydar, Ltd.2021—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 35 years and passes through 7 companies; a new generation was cleared every 4.1 years on median.
  • 6 of the 28 ancestors have a recall of any class.

How does its category compare?

All OWB devices

OWB Interventional Fluoroscopic X-Ray System: FDA decisions, review times, recalls and adverse event reports over 20 years. 2026, this device’s year, is highlighted.

FDA decisions per year · OWB

22in 2025

2007: 32008: 42009: 92010: 72011: 62012: 62013: 112014: 152015: 112016: 162017: 202018: 232019: 92020: 162021: 242022: 212023: 122024: 132025: 222026 (partial year): 15
2007high 24 (2021) · low 3 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · OWB

148in 2025

2007: 52 days median2008: 135 days median2009: 99 days median2010: 66 days median2011: 79 days median2012: 37 days median2013: 119 days median2014: 158 days median2015: 66 days median2016: 103 days median2017: 76 days median2018: 54 days median2019: 174 days median2020: 53 days median2021: 60 days median2022: 90 days median2023: 152 days median2024: 126 days median2025: 148 days median2026 (partial year): 221 days median
2007high 221 (2026) · low 37 (2012)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · OWB

42so far in 2026, the most since 2007

2008: 12013: 102014: 92015: 352016: 132017: 132018: 62019: 72020: 82021: 312022: 242023: 222024: 112025: 302026 (partial year): 42
2007high 42 (2026) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · OWB

14,008in 2025

2007: 12011: 12012: 12013: 272014: 1032015: 2,1342016: 4,0742017: 1,6042018: 1,4492019: 1,5582020: 1,5812021: 1,9812022: 2,9322023: 7,6042024: 7,9422025: 14,008
2007high 14,008 (2025) · low 0 (2008)2025

MAUDE reports naming product code OWB, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200735201
2008413510
200999900
201076600
201167901
201263701
2013111191027
2014151589103
20151166352,134
201616103134,074
20172076131,604
2018235461,449
2019917471,558
2020165381,581
20212460311,981
20222190242,932
202312152227,604
202413126117,942
2025221483014,008
20261522142—

What is it indicated for?

The Cara System is intended for preplanning and guidance of medical interventions in an area known to contain or be adjacent to the cardiac conduction system, such as percutaneous or surgical procedures, for example, transcatheter aortic valve replacement (TAVR), as well as medical procedures where the physician desires to deliver therapy to the patient's cardiac conduction system or to a targeted location within it (CSP). The Cara System uses computed…

Read the full statement (157 words)

The Cara System is intended for preplanning and guidance of medical interventions in an area known to contain or be adjacent to the cardiac conduction system, such as percutaneous or surgical procedures, for example, transcatheter aortic valve replacement (TAVR), as well as medical procedures where the physician desires to deliver therapy to the patient's cardiac conduction system or to a targeted location within it (CSP).

The Cara System uses computed tomography angiography (CTA)-based and user manually marked landmarks to identify the cardiac conduction axis and generate a three-dimensional (3D) map of the individual patient’s cardiac conduction system. The system also overlays the anatomical location of the cardiac conduction system (generated by the Cara Metis Simulator using pre-procedure CT data) onto live fluoroscopic images.

The software utilizes AI/ML algorithms to provide OCR detection, automated segmentation of anatomical structures, and detection of catheters.

The CARA System is intended for use in adult patients (18 years of age and older).

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K252500: CARA System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K252500

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026